Valeria Aguirre Gutierrez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Valeria Aguirre Gutierrez has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Cristian C. Serrano-Mayorga
Unisabana Center for Translational Science, School of Medicine, Universidad de La Sabana, Chia, Colombia
3 shared publications - Luis Felipe Reyes
Universidad de La Sabana
3 shared publications - Luis Fernanda Martinez
Unisabana Center for Translational Science, School of Medicine, Universidad de La Sabana , Chia
3 shared publications - Natalia Sanabria-Herrera
Unisabana Center for Translational Science, School of Medicine, Universidad de La Sabana , Chia
3 shared publications - Alex Julián Forero-Delgadillo
Unisabana Center for Translational Science, School of Medicine, Universidad de La Sabana , Chia
2 shared publications - Ingrid G. Bustos
Unisabana Center for Translational Science, School of Medicine, Universidad de La Sabana , Chia
2 shared publications
Latest Publications
- Open Access
- 29 September 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (10)
Characterization of an Unusual Severe Yellow Fever Outbreak in the Colombian Andean Region
Background: Yellow fever (YF) reemerged in Colombia’s Andean region during 2024–2025, outside the country’s historically recognized endemic areas. We characterized critically ill adults admitted during this outbreak and described clinical features, organ dysfunction, supportive care, and in-hospital outcomes. Methods: We conducted a prospective observational cohort study of consecutive adults with reverse transcription polymerase chain reaction (RT-PCR)–confirmed YF admitted to the national referral intensive care unit in Ibagué, Tolima, Colombia, from March through September 2025. Clinical, laboratory, complication, intervention, and outcome data were prospectively captured using a standardized case report form. Results: Sixty-one patients were analyzed; 22 died (36.1%). Non-survivors had lower platelet counts and fibrinogen and higher INR, aminotransferases, lactate dehydrogenase, and creatinine at ICU admission. Shock, acute kidney injury, acute respiratory distress syndrome, disseminated intravascular coagulation, and severe bleeding were more frequent among non-survivors. Prior YF vaccination was self-reported by 10 patients (16.4%). Conclusions: Severe YF in this Andean outbreak was characterized by hepatic-coagulation abnormalities and multisystem organ dysfunction. The occurrence of critical illness outside historically recognized endemic areas supports surveillance and vaccination strategies that can adapt to changing epidemiological risk.
- 29 September 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (10)
Open AccessCharacterization of an Unusual Severe Yellow Fever Outbreak in the Colombian Andean Region
Background: Yellow fever (YF) reemerged in Colombia’s Andean region during 2024–2025, outside the country’s historically recognized endemic areas. We characterized critically ill adults admitted during this outbreak and described clinical features, organ dysfunction, supportive care, and in-hospital outcomes. Methods: We conducted a prospective observational cohort study of consecutive adults with reverse transcription polymerase chain reaction (RT-PCR)–confirmed YF admitted to the national referral intensive care unit in Ibagué, Tolima, Colombia, from March through September 2025. Clinical, laboratory, complication, intervention, and outcome data were prospectively captured using a standardized case report form. Results: Sixty-one patients were analyzed; 22 died (36.1%). Non-survivors had lower platelet counts and fibrinogen and higher INR, aminotransferases, lactate dehydrogenase, and creatinine at ICU admission. Shock, acute kidney injury, acute respiratory distress syndrome, disseminated intravascular coagulation, and severe bleeding were more frequent among non-survivors. Prior YF vaccination was self-reported by 10 patients (16.4%). Conclusions: Severe YF in this Andean outbreak was characterized by hepatic-coagulation abnormalities and multisystem organ dysfunction. The occurrence of critical illness outside historically recognized endemic areas supports surveillance and vaccination strategies that can adapt to changing epidemiological risk.
- Open Access
- 25 June 2026
- Published by Springer Nature in Pneumonia
- Vol. 18 (1) , 12
Corticosteroids in immunocompromised ICU patients with pneumonia: risks, evidence, and clinical practice
Adjunctive corticosteroids are increasingly used in Severe Community-Acquired Pneumonia (sCAP) requiring admission to the intensive care unit (ICU), based on evidence derived largely from immunocompetent populations. Immunocompromised hosts, however, represent a distinct and growing subgroup among critically ill patients with sCAP, characterised by baseline immune defects, broader pathogen spectra, and a heightened susceptibility to treatment-related harm. Whether corticosteroid strategies validated in the general population can be safely and effectively extrapolated to immunocompromised ICU patients with sCAP remains uncertain, despite their growing use in contemporary ICU practice. Immunocompromised patients admitted to the ICU with sCAP experience compounded alterations in host defence, driven by pre-existing immune dysfunction and superimposed critical illness–associated immune dysregulation. In this setting, corticosteroids may attenuate inflammation-mediated lung injury, but may also deepen immune suppression, distort clinical evolution, and increase susceptibility to opportunistic superinfections and pathogen reactivation. Randomised trials and meta-analyses supporting corticosteroid use in sCAP have systematically excluded immunocompromised patients, treating immunosuppression as an exclusion criterion rather than a stratification variable, and commonly rely on short-term endpoints that fail to capture delayed infectious complications relevant to this population. Available observational data and pathogen-specific evidence suggest substantial heterogeneity of treatment effect (HTE) across immunocompromised subgroups, influenced by immune substrate, pathogen context, and cumulative immunosuppressive burden. Among the pathogen-specific contexts in which corticosteroids have the strongest evidence, Pneumocystis jirovecii pneumonia (PJP) stands out as the principal indication: adjunctive corticosteroids have demonstrated clear mortality benefit in AIDS-associated severe PJP, though this benefit does not extend uniformly to HIV-negative immunocompromised patients with PJP. Consequently, standard corticosteroid treatment in all CAP subgroups is unlikely to be appropriate. In immunocompromised ICU patients with sCAP, corticosteroid therapy should neither be routinely applied nor categorically avoided. Instead, decisions should be individualised, guided by a clearly defined therapeutic target, careful assessment of immune status, and consideration of the risk for opportunistic infections. When used, corticosteroids should be administered at the lowest effective dose and for the shortest feasible duration. Dedicated studies incorporating immune stratification, pathogen-informed approaches, and outcomes relevant to delayed infections are urgently needed. Until such evidence is available, careful risk-balance assessments to decide steroids in these patients.
- 25 June 2026
- Published by Springer Nature in Pneumonia
- Vol. 18 (1) , 12
Open AccessCorticosteroids in immunocompromised ICU patients with pneumonia: risks, evidence, and clinical practice
Adjunctive corticosteroids are increasingly used in Severe Community-Acquired Pneumonia (sCAP) requiring admission to the intensive care unit (ICU), based on evidence derived largely from immunocompetent populations. Immunocompromised hosts, however, represent a distinct and growing subgroup among critically ill patients with sCAP, characterised by baseline immune defects, broader pathogen spectra, and a heightened susceptibility to treatment-related harm. Whether corticosteroid strategies validated in the general population can be safely and effectively extrapolated to immunocompromised ICU patients with sCAP remains uncertain, despite their growing use in contemporary ICU practice. Immunocompromised patients admitted to the ICU with sCAP experience compounded alterations in host defence, driven by pre-existing immune dysfunction and superimposed critical illness–associated immune dysregulation. In this setting, corticosteroids may attenuate inflammation-mediated lung injury, but may also deepen immune suppression, distort clinical evolution, and increase susceptibility to opportunistic superinfections and pathogen reactivation. Randomised trials and meta-analyses supporting corticosteroid use in sCAP have systematically excluded immunocompromised patients, treating immunosuppression as an exclusion criterion rather than a stratification variable, and commonly rely on short-term endpoints that fail to capture delayed infectious complications relevant to this population. Available observational data and pathogen-specific evidence suggest substantial heterogeneity of treatment effect (HTE) across immunocompromised subgroups, influenced by immune substrate, pathogen context, and cumulative immunosuppressive burden. Among the pathogen-specific contexts in which corticosteroids have the strongest evidence, Pneumocystis jirovecii pneumonia (PJP) stands out as the principal indication: adjunctive corticosteroids have demonstrated clear mortality benefit in AIDS-associated severe PJP, though this benefit does not extend uniformly to HIV-negative immunocompromised patients with PJP. Consequently, standard corticosteroid treatment in all CAP subgroups is unlikely to be appropriate. In immunocompromised ICU patients with sCAP, corticosteroid therapy should neither be routinely applied nor categorically avoided. Instead, decisions should be individualised, guided by a clearly defined therapeutic target, careful assessment of immune status, and consideration of the risk for opportunistic infections. When used, corticosteroids should be administered at the lowest effective dose and for the shortest feasible duration. Dedicated studies incorporating immune stratification, pathogen-informed approaches, and outcomes relevant to delayed infections are urgently needed. Until such evidence is available, careful risk-balance assessments to decide steroids in these patients.
- Open Access
- 10 May 2026
- Published by Elsevier in SSRN Electronic Journal
Regional and National Mortality and Aetiologies of Non-Covid Lower Respiratory Infections in Latin America and the Caribbean, 1990–2023: A Systematic Analysis for the Global Burden of Disease Study 2023
Background: Lower respiratory tract infections (LRTIs) remain a leading cause of morbidity and mortality worldwide, with a disproportionate impact in low- and middle-income regions. Reliable, up-to-date burden estimates are essential for informing public health strategies, particularly in Latin America and the Caribbean, where respiratory infections remain a persistent challenge. High incidence strains the healthcare system capacity and quality, while prevention and management strategies remain limited or heterogeneous across countries.Methods: We analysed estimates from the Global Burden of Disease (GBD) 2023 study to quantify the burden of LRTIs in Latin America and the Caribbean between 1990 and 2023. Cause-specific estimates of mortality, incidence, and disability-adjusted life years (DALYs), expressed as years of life lost (YLL) plus years lived with disability (YLD), were extracted from the GBD Results Tool. Estimates were produced following the standardised GBD protocol, coordinated by the Institute for Health Metrics and Evaluation (IHME), which synthesises multiple data sources using validated statistical models.Findings: Globally, LRTIs accounted for 41·0 (36·0–48·0) deaths per 100 000 person-years in 2023, representing a 33·2% decline from 62 (53·0–72·0) per 100 000 in 1990. Within Latin America and the Caribbean, trends were heterogeneous across countries. Mortality rates declined substantially in Chile (from 48·0 [44·1–51·8] to 27·9 [24·1–31·4] deaths per 100 000; annualized rates of change [ARC] -1·63) and Mexico (from 36·3 [33·3–39·8] to 28·2 [24·6–32·3]; ARC -0·76), while reductions were most pronounced among children under five years, notably in Brazil (from 150·6 [131·2–175·2] to 18·5 [15·9–21·3] per 100 000; ARC -6·16) and Chile (from 55·1 [50·6–60·1] to 5·4 [4·3–6·5]; ARC -6·79). DALY rates also declined markedly in several countries, with the largest reductions observed in Peru (from 5771·5 [4896·0–6845·4] to 1629·9 [1357·9–1940·8] per 100 000; ARC -3·76) and Mexico (from 2359·6 [2123·0–2619·1] to 825·5 [727·2–927·7]; ARC -3·13). Following a sustained decline in incidence from 1990 to 2019, the post-COVID-19 era saw a marked reversal across all age groups, with incidence rates rising steadily through 2023, most notably among children under five years in Brazil (ARC +7·919) and Suriname (ARC +8·844), and older adults over 70 years in Cuba (ARC +5·050) and Chile (ARC +5·138). Based on aetiological causes, in 2023 Streptococcus pneumoniae remained the leading agent of LRTI mortality in the region (7·84 [6·99–8·92] deaths per 100 000), followed by Staphylococcus aureus (3·36 [3·02–3·69] deaths per 100 000).Interpretation: LRTIs remain a leading cause of death and disability in Latin America and the Caribbean, yet our findings demonstrate substantial progress in reducing mortality and DALY burden over three decades. We document marked heterogeneity across countries and age groups, with the greatest gains among children under five years old. Shifts in pathogen distribution are evident: S. pneumoniae persists as the leading cause of LRTI mortality, while S. aureus and non-tuberculous mycobacteria (NTM) have emerged as increasingly important contributors. The post-COVID period has reversed prior incidence trends across all age groups, underscoring the vulnerability of regional health systems to pandemic disruptions. These findings highlight the urgent need for sustained investment in vaccination programmes, equitable access to care, and strengthened epidemiological surveillance to reduce the burden of LRTI in the region.
- 10 May 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessRegional and National Mortality and Aetiologies of Non-Covid Lower Respiratory Infections in Latin America and the Caribbean, 1990–2023: A Systematic Analysis for the Global Burden of Disease Study 2023
Background: Lower respiratory tract infections (LRTIs) remain a leading cause of morbidity and mortality worldwide, with a disproportionate impact in low- and middle-income regions. Reliable, up-to-date burden estimates are essential for informing public health strategies, particularly in Latin America and the Caribbean, where respiratory infections remain a persistent challenge. High incidence strains the healthcare system capacity and quality, while prevention and management strategies remain limited or heterogeneous across countries.Methods: We analysed estimates from the Global Burden of Disease (GBD) 2023 study to quantify the burden of LRTIs in Latin America and the Caribbean between 1990 and 2023. Cause-specific estimates of mortality, incidence, and disability-adjusted life years (DALYs), expressed as years of life lost (YLL) plus years lived with disability (YLD), were extracted from the GBD Results Tool. Estimates were produced following the standardised GBD protocol, coordinated by the Institute for Health Metrics and Evaluation (IHME), which synthesises multiple data sources using validated statistical models.Findings: Globally, LRTIs accounted for 41·0 (36·0–48·0) deaths per 100 000 person-years in 2023, representing a 33·2% decline from 62 (53·0–72·0) per 100 000 in 1990. Within Latin America and the Caribbean, trends were heterogeneous across countries. Mortality rates declined substantially in Chile (from 48·0 [44·1–51·8] to 27·9 [24·1–31·4] deaths per 100 000; annualized rates of change [ARC] -1·63) and Mexico (from 36·3 [33·3–39·8] to 28·2 [24·6–32·3]; ARC -0·76), while reductions were most pronounced among children under five years, notably in Brazil (from 150·6 [131·2–175·2] to 18·5 [15·9–21·3] per 100 000; ARC -6·16) and Chile (from 55·1 [50·6–60·1] to 5·4 [4·3–6·5]; ARC -6·79). DALY rates also declined markedly in several countries, with the largest reductions observed in Peru (from 5771·5 [4896·0–6845·4] to 1629·9 [1357·9–1940·8] per 100 000; ARC -3·76) and Mexico (from 2359·6 [2123·0–2619·1] to 825·5 [727·2–927·7]; ARC -3·13). Following a sustained decline in incidence from 1990 to 2019, the post-COVID-19 era saw a marked reversal across all age groups, with incidence rates rising steadily through 2023, most notably among children under five years in Brazil (ARC +7·919) and Suriname (ARC +8·844), and older adults over 70 years in Cuba (ARC +5·050) and Chile (ARC +5·138). Based on aetiological causes, in 2023 Streptococcus pneumoniae remained the leading agent of LRTI mortality in the region (7·84 [6·99–8·92] deaths per 100 000), followed by Staphylococcus aureus (3·36 [3·02–3·69] deaths per 100 000).Interpretation: LRTIs remain a leading cause of death and disability in Latin America and the Caribbean, yet our findings demonstrate substantial progress in reducing mortality and DALY burden over three decades. We document marked heterogeneity across countries and age groups, with the greatest gains among children under five years old. Shifts in pathogen distribution are evident: S. pneumoniae persists as the leading cause of LRTI mortality, while S. aureus and non-tuberculous mycobacteria (NTM) have emerged as increasingly important contributors. The post-COVID period has reversed prior incidence trends across all age groups, underscoring the vulnerability of regional health systems to pandemic disruptions. These findings highlight the urgent need for sustained investment in vaccination programmes, equitable access to care, and strengthened epidemiological surveillance to reduce the burden of LRTI in the region.